Yoshihiro Sakoda Selected Research

Classical Swine Fever (Swine Fever)

1/2021	Efficacy of Oral Vaccine against Classical Swine Fever in Wild Boar and Estimation of the Disease Dynamics in the Quantitative Approach.
1/2021	Characteristics of Classical Swine Fever Virus Variants Derived from Live Attenuated GPE- Vaccine Seed.
3/2020	Development of a High-Throughput Serum Neutralization Test Using Recombinant Pestiviruses Possessing a Small Reporter Tag.
1/2020	A cloned classical swine fever virus derived from the vaccine strain GPE- causes cytopathic effect in CPK-NS cells via type-I interferon-dependent necroptosis.
5/2015	Analysis of a pair of END+ and END- viruses derived from the same bovine viral diarrhea virus stock reveals the amino acid determinants in Npro responsible for inhibition of type I interferon production.
7/2014	Molecular, biological, and antigenic characterization of a Border disease virus isolated from a pig during classical swine fever surveillance in Japan.
8/2012	Development and evaluation of indirect enzyme-linked immunosorbent assay for a screening test to detect antibodies against classical swine fever virus.
2/2004	Cytopathogenicity of classical swine fever viruses that do not show the exaltation of Newcastle disease virus is associated with accumulation of NS3 in serum-free cultured cell lines.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshihiro Sakoda Research Topics

Disease

43	Influenza in Birds (Avian Flu) 01/2022 - 01/2005
34	Infections 01/2022 - 01/2005
25	Human Influenza (Influenza) 11/2021 - 01/2006
13	Virus Diseases (Viral Diseases) 01/2022 - 01/2008
9	Diarrhea 03/2020 - 02/2008
8	Classical Swine Fever (Swine Fever) 01/2021 - 02/2004
3	Pneumonia (Pneumonitis) 01/2022 - 02/2010
2	Inflammation (Inflammations) 01/2021 - 01/2021
2	Viral Pneumonia 01/2021 - 01/2017
2	Disease Progression 01/2021 - 06/2014
2	Coinfection 12/2019 - 02/2010
1	Polycystic Kidney Diseases (Polycystic Kidney Disease) 01/2022
1	COVID-19 01/2022
1	Pestivirus Infections 03/2020
1	Lung Injury 01/2020
1	Persistent Infection 12/2019
1	Hepatitis A (Hepatitis, Infectious) 06/2017
1	Anaphylaxis (Anaphylactic Shock) 01/2017
1	Hypersensitivity (Allergy) 01/2017
1	Vaccinia 11/2016
1	Asymptomatic Infections 10/2014
1	Vesicular Stomatitis 01/2014
1	Multiple Organ Failure (MODS) 01/2013
1	Viremia 08/2012

Drug/Important Bio-Agent (IBA)

34	VaccinesIBA 01/2022 - 05/2007
10	Neuraminidase (Sialidase)IBA 11/2021 - 10/2014
10	Hemagglutinins (Hemagglutinin)IBA 11/2021 - 04/2013
8	Proteins (Proteins, Gene)FDA Link 11/2019 - 02/2004
7	Antiviral Agents (Antivirals)IBA 01/2022 - 04/2013
6	CytokinesIBA 01/2021 - 12/2009
6	AntigensIBA 01/2019 - 01/2005
5	Amino Acids FDA Link 01/2022 - 06/2010
5	Polysaccharides (Glycans)IBA 01/2022 - 02/2013
5	AntibodiesIBA 01/2021 - 11/2006
5	Influenza Vaccines (Influenza Vaccine)FDA Link 01/2017 - 09/2008
4	Oseltamivir (Tamiflu)FDA Link 01/2022 - 05/2016
4	baloxavirIBA 01/2022 - 01/2019
4	Neutralizing AntibodiesIBA 12/2020 - 08/2009
4	Monoclonal AntibodiesIBA 01/2017 - 01/2006
3	EndonucleasesIBA 01/2021 - 12/2018
3	peramivirIBA 12/2020 - 09/2014
3	LuciferasesIBA 03/2020 - 01/2018
2	Phosphates (Orthophosphate)IBA 01/2022 - 01/2022
2	Peptides (Polypeptides)IBA 11/2021 - 01/2012
2	Zanamivir (Relenza)FDA Link 11/2021 - 01/2021
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2010
2	Interferon-alpha (Interferon Alfa)IBA 01/2021 - 01/2020
2	Interleukin-13IBA 01/2021 - 01/2017
2	N-Acetylneuraminic Acid (Sialic Acid)IBA 04/2020 - 09/2013
2	nanolucIBA 03/2020 - 11/2019
2	Biological ProductsIBA 12/2019 - 07/2014
2	Interferon Type IIBA 12/2019 - 05/2015
2	Viral RNAIBA 01/2019 - 12/2018
2	avian influenza A virus hemagglutininIBA 01/2017 - 11/2016
2	feralIBA 12/2013 - 08/2009
2	NucleoproteinsIBA 01/2012 - 01/2006
2	Interleukin-6 (Interleukin 6)IBA 03/2010 - 12/2009
1	AcidsIBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	LipidsIBA 01/2022
1	Sialic AcidsIBA 01/2022
1	Ubiquitin-Specific ProteasesIBA 01/2022
1	Viral Envelope ProteinsIBA 11/2021
1	Attenuated VaccinesIBA 01/2021
1	nafamostatIBA 01/2021
1	Immune Checkpoint ProteinsIBA 01/2021
1	Cell-Penetrating PeptidesIBA 10/2020
1	hydroxide ionIBA 07/2020
1	Calcifediol (Calcidiol)FDA Link 07/2020
1	Interleukin-5 (Interleukin 5)IBA 07/2020
1	Vitamin D FDA LinkGeneric 07/2020
1	Galactose (Galactopyranose)FDA LinkGeneric 04/2020
1	EnzymesIBA 03/2020
1	ImmunosorbentsIBA 03/2020
1	asoxime chloride (H16)IBA 01/2019
1	Nucleic AcidsIBA 01/2019
1	favipiravirIBA 01/2019
1	Therapeutic UsesIBA 01/2019
1	ApolipoproteinsIBA 06/2017
1	Immunoglobulin E (IgE)IBA 01/2017
1	Immunoglobulin A (IgA)IBA 01/2017
1	Formaldehyde (Formol)FDA Link 12/2016
1	Sialyl Lewis X AntigenIBA 02/2016
1	ZincIBA 05/2015
1	Immunoglobulin G (IgG)IBA 10/2014
1	C-Type Lectins (C-Type Lectin)IBA 01/2014
1	Cathepsin LIBA 01/2014
1	Basic Amino Acids (Basic Amino Acid)IBA 12/2013
1	sialooligosaccharidesIBA 09/2013
1	ChemokinesIBA 01/2013
1	Sulfates (Sulfates, Inorganic)IBA 07/2012
1	EstersIBA 07/2012
1	CelluloseIBA 07/2012
1	cellulose sulfateIBA 07/2012
1	Nucleocapsid ProteinsIBA 12/2011
1	Glutamine (L-Glutamine)FDA Link 06/2010
1	Indicators and Reagents (Reagents)IBA 06/2010
1	Ether (Diethyl Ether)IBA 06/2010

Therapy/Procedure

2	Therapeutics 01/2020 - 06/2014
2	Intranasal Administration 01/2017 - 12/2009